{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:17Z","timestamp":1781639597913,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes and chronic kidney disease (CKD) heart failure with preserved ejection fraction is associated with considerable morbidity and it has fewer treatment options available. HFpEF, which is characterized by increased cardiovascular risks and poor outcomes, continues to be a therapeutic challenge, particularly in older persons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>A non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone has excellent therapeutic potential in patients with HFpEF and CKD, notably those with diabetes type 2. Research indicate that Finerenone preferentially targets mineralocorticoid receptors associated with inflammation and fibrosis and that it also has an advantage over commonly used steroidal MRAs (e.g., spironolactone), which carry significant risks such as hyperkalemia, gynecomastia, and renal impairment. There are two phase 3 clinical trials namely FIDELIO-DKD and FIGARO-DKD demonstrating how effectively finerenone works in preventing the progression of renal damage and cardiovascular events in type 2 diabetic patients and in patients with CKD. In addition, the FINEARTS-HF study shows that hospitalizations for heart failure were reduced with use of finerenone and also the overall decline in individuals with HFpEF across all ages, particularly the older populations. Finally, Finerenone is found to be more appropriate for patients with complex medical histories because its safety profile shows fewer side effects compared to the traditional steroidal MRAs, as it has lower risks for electrolyte imbalances and renal function deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This article addresses the safety, efficacy, mechanism of action, and various trials conducted on Finerenone and how it gained importance as an effective substitute in the management of HFpEF and CKD, decreasing morbidity and mortality risks while limiting adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43044-026-00722-x","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T14:28:06Z","timestamp":1772375286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review"],"prefix":"10.1186","volume":"78","author":[{"given":"Muhammad Shaheer Bin","family":"Faheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza","family":"Qurat Ul Ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatka","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasra","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Own E Mohammad","family":"Najmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"issue":"Suppl 2","key":"722_CR1","doi-asserted-by":"publisher","first-page":"s24","DOI":"10.7861\/clinmedicine.18-2-s24","volume":"18","author":"AR Harper","year":"2018","unstructured":"Harper AR, Patel HC, Lyon AR (2018) Heart failure with preserved ejection fraction. Clin Med (Lond) 18(Suppl 2):s24\u2013s29. https:\/\/doi.org\/10.7861\/clinmedicine.18-2-s24PMID: 29700089; PMCID: PMC6334030","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"722_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10741-025-10585-0","volume":"31","author":"A Pozzi","year":"2025","unstructured":"Pozzi A, Spoladore R, Iorio A, Corrado G, D\u2019Amario D (2025) Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients\u2019 management. Heart Fail Rev 31(1):3","journal-title":"Heart Fail Rev"},{"issue":"2","key":"722_CR3","doi-asserted-by":"publisher","first-page":"151516","DOI":"10.1016\/j.semnephrol.2024.151516","volume":"44","author":"ML Tuttle","year":"2024","unstructured":"Tuttle ML, Fang JC, Sarnak MJ, McCallum W (2024) Epidemiology and management of patients with kidney disease and heart failure with preserved ejection fraction. Semin Nephrol 44(2):151516","journal-title":"Semin Nephrol"},{"issue":"23","key":"722_CR4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845Epub 2020 Oct 23. PMID: 33264825","journal-title":"N Engl J Med"},{"issue":"10","key":"722_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"722_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","volume":"24","author":"P Rossing","year":"2022","unstructured":"Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Amod A, Marre M, Joseph A, Lage A, Scott C (2022) Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO\u2010DKD trial. Diabetes Obes Metabolism 24(1):125\u2013134","journal-title":"Diabetes Obes Metabolism"},{"key":"722_CR7","doi-asserted-by":"publisher","unstructured":"Chimura M, Petrie MC, Schou M, Martinez FA, Henderson AD, Claggett BL, Desai AS, Kolkhof P, Viswanathan P, Lage A, Lam CSP, Senni M, Shah SJ, Rohwedder K, Mueller K, Voors AA, Zannad F, Pitt B, Vaduganathan M, Jhund PS, Solomon S, McMurray JJV (2024) Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF. Circ Heart Fail. 29. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012437. Epub ahead of print. PMID: 39342655","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437"},{"key":"722_CR8","first-page":"784","volume":"112","author":"ET Mesquita","year":"2019","unstructured":"Mesquita ET, Barbetta LM, Correia ET (2019) Heart failure with mid-range ejection fraction-State of the art. Arquivos brasileiros de cardiologia 112:784\u2013790","journal-title":"Arquivos brasileiros de cardiologia"},{"issue":"10","key":"722_CR9","first-page":"17119","volume":"135","author":"A Dory\u0144ska","year":"2025","unstructured":"Dory\u0144ska A, Drohomirecka A, Top\u00f3r-M\u0105dry R, \u0141azarczyk H, Zieli\u0144ski T, Rywik TM (2025) Changes in the prevalence of heart failure phenotypes over time and their association with patient prognosis. Pol Archives Intern Med 135(10):17119","journal-title":"Pol Archives Intern Med"},{"issue":"7","key":"722_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/eurjhf\/hft028","volume":"15","author":"V Lazzarini","year":"2013","unstructured":"Lazzarini V, Mentz RJ, Fiuzat M, Metra M, O\u2019Connor CM (2013) Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 15(7):717\u2013723. https:\/\/doi.org\/10.1093\/eurjhf\/hft028Epub 2013 Feb 20. PMID: 23429975; PMCID: PMC4176107","journal-title":"Eur J Heart Fail"},{"key":"722_CR11","doi-asserted-by":"publisher","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, Eitner F, Albrecht-K\u00fcpper B, Sch\u00e4fer S (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. ;64(1):69\u201378. https:\/\/doi.org\/10.1097\/FJC.0000000000000091. PMID: 24621652","DOI":"10.1097\/FJC.0000000000000091"},{"issue":"24","key":"722_CR12","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM (2021) FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956Epub 2021 Aug 28. PMID: 34449181","journal-title":"N Engl J Med"},{"key":"722_CR13","doi-asserted-by":"publisher","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL (2022) FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. ;43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777. Erratum in: Eur Heart J. 2022;43(20):1989. doi: 10.1093\/eurheartj\/ehab886. PMID: 35023547; PMCID: PMC8830527","DOI":"10.1093\/eurheartj\/ehab777"},{"issue":"6","key":"722_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B (2022) FIGARO-DKD Investigators. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145(6):437\u2013447 Epub 2021 Nov 13. PMID: 34775784; PMCID: PMC8812430","journal-title":"Circulation"},{"issue":"31","key":"722_CR15","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463. https:\/\/doi.org\/10.1093\/eurheartj\/eht187Epub 2013 May 27. PMID: 23713082; PMCID: PMC3743070","journal-title":"Eur Heart J"},{"issue":"27","key":"722_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37(27):2105\u20132114. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132Epub 2016 Apr 29. PMID: 27130705; PMCID: PMC4946749","journal-title":"Eur Heart J"},{"issue":"6","key":"722_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","volume":"26","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD (2024) Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail 26(6):1324\u20131333. https:\/\/doi.org\/10.1002\/ejhf.3253Epub 2024 May 14. PMID: 38742248","journal-title":"Eur J Heart Fail"},{"key":"722_CR18","doi-asserted-by":"crossref","unstructured":"Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ (2015) Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol. ;200:15\u2009\u2013\u20099. doi: 10.1016\/j.ijcard.2015.07.038. PMID: 26404747","DOI":"10.1016\/j.ijcard.2015.07.038"},{"issue":"4","key":"722_CR19","doi-asserted-by":"publisher","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","volume":"37","author":"NR Desai","year":"2023","unstructured":"Desai NR, Navaneethan SD, Nicholas SB, Pantalone KM, Wanner C, Hamacher S, Gay A, Wheeler DC (2023) Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice. J Diabetes Complications 37(4):108411 Epub 2023 Feb 2. PMID: 36857997","journal-title":"J Diabetes Complications"},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/ph17040418","volume":"17","author":"N Piko","year":"2024","unstructured":"Piko N, Bevc S, Hojs R, Ekart R, Finerenone (2024) From the mechanism of action to clinical use in kidney disease. Pharmaceuticals 17:418. https:\/\/doi.org\/10.3390\/ph17040418","journal-title":"Pharmaceuticals"},{"issue":"2","key":"722_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.17925\/EE.2021.17.2.84","volume":"17","author":"L D\u2019Marco","year":"2021","unstructured":"D\u2019Marco L, Puchades MJ, Gand\u00eda L, Forquet C, Gim\u00e9nez-Civera E, Panizo N, Reque J, Juan-Garc\u00eda I, Berm\u00fadez V, Gorriz JL (2021) Finerenone: a potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus. touchREV Endocrinol 17(2):84\u201387 Epub 2021 Nov 10. PMID: 35118452; PMCID: PMC8676102","journal-title":"touchREV Endocrinol"},{"issue":"10","key":"722_CR22","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1111\/dom.15773","volume":"26","author":"MA Escobar Vasco","year":"2024","unstructured":"Escobar Vasco MA, Fantaye SH, Raghunathan S, Solis-Herrera C (2024) The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease. Diabetes Obes Metab 26(10):4135\u20134146. https:\/\/doi.org\/10.1111\/dom.15773Epub 2024 Jul 18. PMID: 39021345","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"722_CR23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/ajhp\/zxad192","volume":"80","author":"E Ashjian","year":"2023","unstructured":"Ashjian E, Clarke M, Pogue K (2023) Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health Syst Pharm 80(23):1708\u20131721. https:\/\/doi.org\/10.1093\/ajhp\/zxad192PMID: 37632460; PMCID: PMC10664185","journal-title":"Am J Health Syst Pharm"},{"key":"722_CR24","doi-asserted-by":"publisher","unstructured":"Epstein M (2011) Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts. Kidney Int Suppl 2022;12(1):69\u201375. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.008. Epub 2022 Mar 18. PMID: 35529085; PMCID: PMC9073253","DOI":"10.1016\/j.kisu.2021.11.008"},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/TCRM.S325916","volume":"18","author":"A Shaikh","year":"2022","unstructured":"Shaikh A, Ray J, Campbell KN (2022) Role of finerenone in the treatment of diabetic kidney disease: patient selection and clinical perspectives. Ther Clin Risk Manag 18:753\u2013760 PMID: 35937973; PMCID: PMC9346301","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"722_CR26","doi-asserted-by":"publisher","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","volume":"14","author":"S Bansal","year":"2024","unstructured":"Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B (2024) Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open 14(3):e076444. https:\/\/doi.org\/10.1136\/bmjopen-2023-076444PMID: 38508632; PMCID: PMC10952937","journal-title":"BMJ Open"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-026-00722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-026-00722-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-026-00722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:07:21Z","timestamp":1781636841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43044-026-00722-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1186\/s43044-026-00722-x","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}